Motolimod (VTX-2337) is a specific TLR8 agonist that activates NK cells and augments antibody-dependent cellular cytotoxicity (ADCC).103 In addition, motolimod can facilitate the activation of NK cells and dendritic cell cross-priming of tumor specific CD8+ T cells in head and neck cancer.104. Here, CD8A is linked to neoplasm.